Inhibitory activity of INCB040093 against human primary immune cell
| Primary Cell | Stimulant | Response | IC50 (nM)a |
|---|---|---|---|
| B (CD21+; canine) | Anti-dog IgM | Proliferation | 2.1 ± 0.01 |
| B (CD19+; human) | Anti-human IgM | Proliferation | 2.4 ± 0.5 |
| B (CD19+; human) | LPS | Proliferation | 0.9 ± 0.3 |
| B (CD19+; human) | IL-4 | Proliferation | 3.8 ± 2.1 |
| B (CD19+; human) | IL-6 | Proliferation | 1.7 ± 0.3 |
| B (CD19+; human) | BAFF | Proliferation | 1.2 ± 0.8 |
| B (CD19+; human) | Anti-CD40 | Proliferation | 3.2 ± 1.0 |
| B (CD19+; human) | CD40 ligand | Proliferation | 2.8 ± 1.8 |
| Basophilb | Anti-Fcε receptor | CD63 expression | 35 ± 15 |
| T (CD4+CD45RA+, human) | Th17 cocktailc | Th17 differentiation | 3.9 ± 3 |
| T (total T cellsd, human) | Anti-CD3 | Proliferation | 2133 ± 1122 |
| T (total T cellsd, human) | Anti-CD28 | Proliferation | 130 ± 31 |
| T (total T cellsd, human) | Anti-CD28 and anti-CD3 | Proliferation | 1753 ± 632 |
| T (CD3+, human) | IL-2 | Proliferation | 3107 ± 1371 |
| NK (CD56+, human) | IL-2 | Proliferation | 708 ± 50 |
| Neutrophil (human) | fMLP | Elastase exocytosis | 1566 ± 545 |
| PBMC (human) | LPS | TNF-α production | 2704 (n = 1) |
| Monocytes (human) | CCL2 | Chemotaxis | >10,000 |